Comparison of trials
| . | EuroNet-PHL-C1 . | EuroNet-PHL-C2 . | AHOD1331 . |
|---|---|---|---|
| Dates of enrollment | 31 January 2007 to 30 January 2013 | 1 October 2015 to 31 December 2020 | 16 March 2015 to 2 August 2019 |
| Median follow-up | 66.5 mo (IQR, 62.7-71.7) | N/A (follow-up ongoing at time of publication) | 42.1 mo (range, 0.1-80.9) |
| Ages enrolled | <18 y | <25 y | 2-21 y |
| Risk groups included in trial | Early (TG-1): IA, IB, and IIA Intermediate (TG-2): IAE, IBE, IIB, IIAE, and IIIA Advanced (TG-3): IIBE, IIIAE, IIIB, IIIBE, all IV | Early (TL-1): IA, IB, and IIA without risk factors (either bulk >200 mL or ESR >30 mm/h) Intermediate (TL-2): IA, IE, IIA + risk factors or IIB, IIIA Advanced (TL-3): IIBE, IIIAE, IIIB, IIIE, IIIBE, all IV | High risk (HR): IIB + bulk, IIIB, all IV |
| Time of randomization | After 2 courses of initial chemotherapy and interim FDG-PET | After 2 courses of initial chemotherapy and interim FDG-PET | Before treatment initiation |
| Induction treatment | 2 × OEPA (vincristine, etoposide, prednisone, doxorubicin) | 2 × OEPA (vincristine, etoposide, prednisone, doxorubicin) | 2 × ABVE-PC (adriamycin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide) or 2 × Bv-AVE-PC (brentuximab vedotin, adriamycin, vincristine, etoposide, prednisone, cyclophosphamide) |
| Chemotherapy treatment after interim FDG-PET | 2 (IR) or 4 (HR) × COPP (cyclophosphamide, vincristine, prednisone, procarbazine) or 2 (IR) or 4 (HR) × COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine) | 2 (TL-2) or 4 (TL-3) × COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine) or 2 (TL-2) or 4 (TL-3) × DECOPDAC (doxorubicin, etoposide, cyclophosphamide, vincristine, prednisone, dacarbazine) | 3 additional cycles of chemotherapy based on randomization before treatment start (3 × ABVE-PC or 3 × Bv-AVE-PC) |
| Indication for radiotherapy | All initially involved sites (except for bone marrow lesions) if interim FDG-PET was positive (Deauville score 3, 4, or 5) or volume reduction <50% | COPDAC group: All initially involved sites (except for bone marrow lesions) if interim FDG-PET was positive (Deauville score >3) plus boost on lesions still FDG-PET positive (Deauville score >3) at the end of chemotherapy or DECOPDAC group: 30 Gy on all lesions still FDG-PET positive (Deauville score >3) at the end of chemotherapy | Large mediastinal adenopathy and all sites which were still positive (Deauville score 4 or 5) in interim FDG-PET |
| . | EuroNet-PHL-C1 . | EuroNet-PHL-C2 . | AHOD1331 . |
|---|---|---|---|
| Dates of enrollment | 31 January 2007 to 30 January 2013 | 1 October 2015 to 31 December 2020 | 16 March 2015 to 2 August 2019 |
| Median follow-up | 66.5 mo (IQR, 62.7-71.7) | N/A (follow-up ongoing at time of publication) | 42.1 mo (range, 0.1-80.9) |
| Ages enrolled | <18 y | <25 y | 2-21 y |
| Risk groups included in trial | Early (TG-1): IA, IB, and IIA Intermediate (TG-2): IAE, IBE, IIB, IIAE, and IIIA Advanced (TG-3): IIBE, IIIAE, IIIB, IIIBE, all IV | Early (TL-1): IA, IB, and IIA without risk factors (either bulk >200 mL or ESR >30 mm/h) Intermediate (TL-2): IA, IE, IIA + risk factors or IIB, IIIA Advanced (TL-3): IIBE, IIIAE, IIIB, IIIE, IIIBE, all IV | High risk (HR): IIB + bulk, IIIB, all IV |
| Time of randomization | After 2 courses of initial chemotherapy and interim FDG-PET | After 2 courses of initial chemotherapy and interim FDG-PET | Before treatment initiation |
| Induction treatment | 2 × OEPA (vincristine, etoposide, prednisone, doxorubicin) | 2 × OEPA (vincristine, etoposide, prednisone, doxorubicin) | 2 × ABVE-PC (adriamycin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide) or 2 × Bv-AVE-PC (brentuximab vedotin, adriamycin, vincristine, etoposide, prednisone, cyclophosphamide) |
| Chemotherapy treatment after interim FDG-PET | 2 (IR) or 4 (HR) × COPP (cyclophosphamide, vincristine, prednisone, procarbazine) or 2 (IR) or 4 (HR) × COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine) | 2 (TL-2) or 4 (TL-3) × COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine) or 2 (TL-2) or 4 (TL-3) × DECOPDAC (doxorubicin, etoposide, cyclophosphamide, vincristine, prednisone, dacarbazine) | 3 additional cycles of chemotherapy based on randomization before treatment start (3 × ABVE-PC or 3 × Bv-AVE-PC) |
| Indication for radiotherapy | All initially involved sites (except for bone marrow lesions) if interim FDG-PET was positive (Deauville score 3, 4, or 5) or volume reduction <50% | COPDAC group: All initially involved sites (except for bone marrow lesions) if interim FDG-PET was positive (Deauville score >3) plus boost on lesions still FDG-PET positive (Deauville score >3) at the end of chemotherapy or DECOPDAC group: 30 Gy on all lesions still FDG-PET positive (Deauville score >3) at the end of chemotherapy | Large mediastinal adenopathy and all sites which were still positive (Deauville score 4 or 5) in interim FDG-PET |
IQR, interquartile range; HR, high risk; IR, intermediate risk; N/A, not applicable.